A Novel Liquid Biopsy Spectroscopy Method for Early Detection of Brain Tumors
|
By LabMedica International staff writers Posted on 16 Aug 2021 |
|
Image: Highly effective early diagnostic tests could revolutionize cancer detection. Here, a sample is dropped onto a disposable Dxcover Slide and dried for analysis (Photo courtesy of Dxcover Limited)
A blood-based liquid biopsy approach enables detection of brain tumors that are so small and low-grade that the patient will often have few or no symptoms.
Due to the non-specific symptoms of brain cancer, gliomas will often remain undetected until they are larger or at a higher grade, reducing the patient’s likelihood of a good clinical outcome. Earlier detection and diagnosis of brain tumors is vital to improve patient outcomes, leading to safer surgeries and earlier treatments.
In this regard, investigators at the University of Strathclyde (Glasgow, United Kingdom) and the biotech company Dxcover Limited (Glasgow, United Kingdom) developed a Multi Cancer Early Detection (MCED) Platform based on a spectroscopic liquid biopsy approach for detection of small and low-grade gliomas.
This approach combined attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy coupled with supervised learning methods and machine learning algorithms for the analysis of dried blood samples.
The current study was carried out on a cohort of 177 patients (90 patients with high-grade glioma (glioblastoma (GBM) or anaplastic astrocytoma), or low-grade glioma (astrocytoma, oligoastrocytoma, and oligodendroglioma). Tumor volumes were calculated from magnetic resonance imaging (MRI) investigations and patients were split into two groups depending on MRI parameters. Combining the spectroscopy technology with supervised learning methods and machine learning algorithms, 90 tumor patients were stratified against 87 control patients who displayed no symptomatic indications of cancer, and were classified as either glioma or non-glioma.
Results revealed that sensitivities, specificities, and balanced accuracies were all greater than 88%, the area under the curve (AUC) was 0.98, and cancer patients with tumor volumes as small as 0.2 cubic centimeters were correctly identified.
Senior author Dr. Matthew Baker, chief technical officer of Dxcover Limited, said, "This breakthrough is a watershed moment in the development of early cancer detection. The study demonstrates the effectiveness of our Dxcover Brain Cancer Liquid Biopsy at detecting even the smallest brain tumors, which is great news for the care of future brain cancer patients, increasing treatment options and potentially extending life expectancy. Clinical tests like this are a crucial part of Dxcover's journey to develop and commercialize a widely accepted Multi-Cancer Early Detection platform to help save lives."
The liquid biopsy for early glioma detection was described in the July 30, 2021, online edition of the journal Cancers.
Related Links:
University of Strathclyde
Dxcover Limited
Due to the non-specific symptoms of brain cancer, gliomas will often remain undetected until they are larger or at a higher grade, reducing the patient’s likelihood of a good clinical outcome. Earlier detection and diagnosis of brain tumors is vital to improve patient outcomes, leading to safer surgeries and earlier treatments.
In this regard, investigators at the University of Strathclyde (Glasgow, United Kingdom) and the biotech company Dxcover Limited (Glasgow, United Kingdom) developed a Multi Cancer Early Detection (MCED) Platform based on a spectroscopic liquid biopsy approach for detection of small and low-grade gliomas.
This approach combined attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy coupled with supervised learning methods and machine learning algorithms for the analysis of dried blood samples.
The current study was carried out on a cohort of 177 patients (90 patients with high-grade glioma (glioblastoma (GBM) or anaplastic astrocytoma), or low-grade glioma (astrocytoma, oligoastrocytoma, and oligodendroglioma). Tumor volumes were calculated from magnetic resonance imaging (MRI) investigations and patients were split into two groups depending on MRI parameters. Combining the spectroscopy technology with supervised learning methods and machine learning algorithms, 90 tumor patients were stratified against 87 control patients who displayed no symptomatic indications of cancer, and were classified as either glioma or non-glioma.
Results revealed that sensitivities, specificities, and balanced accuracies were all greater than 88%, the area under the curve (AUC) was 0.98, and cancer patients with tumor volumes as small as 0.2 cubic centimeters were correctly identified.
Senior author Dr. Matthew Baker, chief technical officer of Dxcover Limited, said, "This breakthrough is a watershed moment in the development of early cancer detection. The study demonstrates the effectiveness of our Dxcover Brain Cancer Liquid Biopsy at detecting even the smallest brain tumors, which is great news for the care of future brain cancer patients, increasing treatment options and potentially extending life expectancy. Clinical tests like this are a crucial part of Dxcover's journey to develop and commercialize a widely accepted Multi-Cancer Early Detection platform to help save lives."
The liquid biopsy for early glioma detection was described in the July 30, 2021, online edition of the journal Cancers.
Related Links:
University of Strathclyde
Dxcover Limited
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Auto Clinical Chemistry Analyzer
cobas c 703
Latest Molecular Diagnostics News
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
- Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
- Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer
- New Bowel Cancer Blood Test to Improve Early Detection
- Refined Test Improves Parkinson’s Disease Diagnosis
- New Method Rapidly Diagnoses CVD Risk Via Molecular Blood Screening
- Blood Test Shows Promise for Early Detection of Dementia
- CRISPR-Based Diagnostic Test Detects Pathogens in Blood Without Amplification
- Portable Blood-Based Device Detects Colon Cancer
- New DNA Test Diagnoses Bacterial Infections Faster and More Accurately
- Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Pathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read more
Industry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more
